Advice
Following an abbreviated submission
darunavir (Prezista ) is accepted for use within NHS Scotland, co-administered with low dose ritonavir in combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus (HIV-1) infection in highly pre-treated children and adolescents, from the age of 6 years and at least 20kg body weight, who have failed on more than one regimen containing a protease inhibitor (PI).
Darunavir is listed in the British National Formulary for Children for the treatment of HIV resistant to other protease inhibitors. The Scottish Medicines Consortium has previously accepted this product for use in this indication in adults.
Download detailed advice51KB (PDF)
Medicine details
- Medicine name:
- darunavir (Prezista)
- SMC ID:
- 604/10
- Indication:
- HIV in children and adolescents
- Pharmaceutical company
- Tibotec (Janssen-Cilag Ltd)
- BNF chapter
- Infections
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 08 February 2010